New cancer clinical trial: A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Published on: November 28, 2018 at 12:00PM
Condition:   Prostate Cancer
Interventions:   Drug: DKN-01 300 mg;   Drug: DKN-01 600 mg;   Drug: Docetaxel 75 mg/m2;   Drug: DKN-01 de-escalated 150 mg
Sponsor:   New York University School of Medicine
Not yet recruiting
https://ift.tt/2FOa4uc